Efficacy and safety of glycopyrrolate/eFlow ® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials.

MLA

Kerwin, Edward, et al. “Efficacy and Safety of Glycopyrrolate/EFlow ® CS (Nebulized Glycopyrrolate) in Moderate-to-Very-Severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 Randomized Controlled Trials.” Respiratory Medicine, vol. 132, Nov. 2017, pp. 238–50. EBSCOhost, https://doi.org/10.1016/j.rmed.2017.07.011.

APA

Kerwin, E., Donohue, J. F., Goodin, T., Tosiello, R., Wheeler, A., & Ferguson, G. T. (2017). Efficacy and safety of glycopyrrolate/eFlow ® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respiratory Medicine, 132, 238–250. https://doi.org/10.1016/j.rmed.2017.07.011

Chicago

Kerwin, Edward, James F Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler, and Gary T Ferguson. 2017. “Efficacy and Safety of Glycopyrrolate/EFlow ® CS (Nebulized Glycopyrrolate) in Moderate-to-Very-Severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 Randomized Controlled Trials.” Respiratory Medicine 132 (November): 238–50. doi:10.1016/j.rmed.2017.07.011.